MedTrace Logo

Predict the Response to Acute Treatment of Migraine With Rimegepant 75 mg

NCT05888766 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2023-06-05

No results posted yet for this study

Summary

Tools to predict which patients could better respond to abortive CGRP target therapy are still lacking. We propose to investigate if biochemical (salivary CGRP) and neurophysiological (evoked potentials) biomarkers can recognize patients with the best chances of responding to Rimegepant 75 mg as an acute treatment of migraine.

Conditions

  • Migraine Disorders

Interventions

DRUG

Rimegepant 75 milligrams

At the screening visit patients with episodic migraine, which will be prescribed Rimegepant 75 mg as abortive treatment, will be asked to participate in the study.

Sponsors & Collaborators

  • University of Roma La Sapienza

    lead OTHER

Principal Investigators

  • Gabriele Sebastianelli, MD · University of Roma La Sapienza

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2024-07-30
Completion
2024-09-30
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05888766 on ClinicalTrials.gov